Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Lyrica

    - PMLiVE

    Medicus Pharma completes patient enrolment for basal cell carcinoma trial

    Interim results have shown over 60% clinical clearance in patients treated with SkinJect

    - PMLiVE

    Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

    Around 9,000 people in the US currently live with SMA

    - PMLiVE

    Novartis announces plans for new US manufacturing hub

    The US hub is expected to create 700 new jobs by 2030

    - PMLiVE

    Novartis reports primary endpoint reached in phase 3 malaria trial

    The treatment demonstrated non-inferiority to current standard of care

    - PMLiVE

    J&J receives positive NICE recommendation for multiple myeloma treatment

    The treatment is approved for use within the NHS in England and Wales

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    Medicus Pharma recruits first patient in cancer patch trial

    The first patient has been dosed as part of a phase 2 trial in the UAE

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    Novartis presents new positive data for rheumatic autoimmune disease treatment

    Patient outcome benefits were observed in two ongoing phase 3 trials

    - PMLiVE

    Novartis to acquire Avidity Biosciences in deal worth $12bn

    The acquisition will expand Novartis’ neuroscience pipeline

    - PMLiVE

    Novartis announces new data supporting MS therapy Kesimpta

    The latest trial results reinforce the drug's long-term efficacy and safety profile

    - PMLiVE

    Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

    Novartis will gain cardiovascular treatment option pacibekitug

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links